5-APDI Stats & Data

Identity/mislabelling risk: “IAP/5‑IAP/5‑APDI” has been inconsistently named and sometimes mis-sold; historical misrepresentation (e.g., 5‑IAI fiasco) underscores the need for GC/MS drug checking over reagent kits alone. Purity and identity should be verified where possible. Slow onset and long tail make premature redosing risky; tolerance can build intra‑session, leading to greater side‑effects with little added benefit. As a serotonergic releaser, it carries serotonin syndrome risk—especially with MAOIs, SSRIs/SNRIs, tramadol/meperidine, linezolid, and other SRAs. Hyperthermia is possible in warm, crowded settings; take cooling breaks, avoid vigorous exertion, and maintain light, spaced fluids. Conversely, overhydration can cause hyponatraemia; sip small amounts regularly and consider electrolytes rather than rapid overconsumption of water. GI side‑effects (nausea, cramping, diarrhoea) are common with serotonergic drugs given the high proportion of peripheral 5‑HT in the gut. Cardiovascular strain (tachycardia, sweating) and bruxism are frequently reported; avoid combining with other stimulants. Insufflation increases local irritation; avoid repeated lines. Intravenous use is strongly discouraged due to unknown solubility/excipients and lack of clinical formulation. Space sessions widely (several weeks) to reduce tolerance and mood after‑effects, by analogy to MDMA‑like agents. Use a thermometer if active for long periods; if overheating or severe agitation/confusion/tremor/clonus occur, seek medical help; benzodiazepines and external cooling are standard first‑aid while awaiting care.